Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
[
Title
]
Type
Year
Filters:
Author
is
Kersten, Marie José
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
T
Brink M
,
Huisman F
,
Meeuwes FOkko
,
van der Poel MWM
,
Kersten MJosé
,
Wondergem MJ
,
Böhmer LH
,
Woei-A-Jin FJSherida
,
Visser OJ
,
Oostvogels R
, et al.
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry.
Blood Adv. 2024.
PubMed
Google Scholar
Awasthi R
,
Pacaud L
,
Waldron E
,
Tam CS
,
Jäger U
,
Borchmann P
,
Jaglowski S
,
Foley SRonan
,
van Besien K
,
Wagner-Johnston ND
, et al.
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.
Blood Adv. 2020;4(3):560-572.
PubMed
Google Scholar
P
Sonneveld P
,
Asselbergs E
,
Zweegman S
,
van der Holt B
,
Kersten MJosé
,
Vellenga E
,
van Marwijk-Kooy M
,
Broyl A
,
de Weerdt O
,
Lonergan S
, et al.
Phase 2 study of carfilzomib, thalidomide and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.
Blood. 2014.
PubMed
Google Scholar
L
Schuster SJ
,
Tam CS
,
Borchmann P
,
Worel N
,
McGuirk JP
,
Holte H
,
Waller EK
,
Jaglowski S
,
Bishop MR
,
Damon LE
, et al.
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol. 2021.
PubMed
Google Scholar
I
Meeuwes FO
,
Brink M
,
van der Poel MWM
,
Kersten MJosé
,
Wondergem M
,
Mutsaers PGNJ
,
Böhmer L
,
Woei-A-Jin S
,
Visser O
,
Oostvogels R
, et al.
Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis.
Eur J Cancer. 2022;176:100-109.
PubMed
Google Scholar
Brink M
,
Meeuwes FO
,
van der Poel MWM
,
Kersten MJosé
,
Wondergem M
,
Mutsaers PGNJ
,
Böhmer LH
,
Woei-A-Jin FJSherida
,
Visser O
,
Oostvogels R
, et al.
Impact of Etoposide and ASCT on Survival Among Patients <65 years With Stage II-IV PTCL; a Population-Based Cohort Study.
. Blood. 2022.
PubMed
Google Scholar
H
Persoon S
,
Kersten MJosé
,
Buffart LM
,
Slagmolen GVander
,
Baars JW
,
Visser O
,
Manenschijn A
,
Nollet F
,
Chinapaw MJM
.
Health-related physical fitness in patients with multiple myeloma or lymphoma recently treated with autologous stem cell transplantation.
J Sci Med Sport. 2016.
PubMed
Google Scholar
E
Mank APM
,
Schoonenberg C
,
Bleeker K
,
Heijmenberg S
,
de Heer K
,
van Oers MHJ
,
Kersten MJosé
.
Early discharge after high dose chemotherapy is safe and feasible: a prospective evaluation of 6 years of home care.
Leuk Lymphoma. 2014:1-20.
PubMed
Google Scholar
D
Dreyling M
,
Fowler NH
,
Dickinson M
,
Martínez-López J
,
Kolstad A
,
Butler J
,
Ghosh M
,
Popplewell L
,
Chavez JC
,
Bachy E
, et al.
Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update.
Blood. 2024.
PubMed
Google Scholar
C
Sureda A
,
Lugtenburg PJ
,
Kersten MJosé
,
Subklewe M
,
Spanjaart A
,
Shah NN
,
Kerbauy LN
,
Roddie C
,
Pennings ERA
,
Mahuad C
, et al.
Cellular therapy in lymphoma.
Hematol Oncol. 2023.
PubMed
Google Scholar
B
Driessen J
,
de Wit F
,
Herrera AF
,
Zinzani PLuigi
,
Lacasce AS
,
Cole PD
,
Moskowitz CH
,
Garcia-Sanz R
,
Fuchs M
,
Mueller H
, et al.
Brentuximab Vedotin and Chemotherapy in Relapsed/Refractory Hodgkin Lymphoma: a Propensity Score Matched Analysis.
Blood Adv. 2024.
PubMed
Google Scholar